ATM-heterozygous germline mutations were shown to contribute to breast cancer, non-Hodgkin’s lymphomas and B-cell chronic lymphocytic leukemia, while ATM-homozygotes develop lymphoma and leukemia [110, 111]. Here, ATM is linked to non-Hodgkin lymphoma.